PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today announced that the Chinese State Food and Drug Administration (SFDA) has approved Microcyn® Technology for use in China. The Chinese agency approved Microcyn Technology for treatment of various acute and chronic wounds including ulcers, cuts, contusions and burns. This approval allows Oculus’ Chinese partner to market Microcyn Technology as a technology that provides a moist environment for wounds and accelerates wound healing through the reduction of microorganisms in wounds.
